London, September 12
British clinical trials of the Oxford University and AstraZeneca coronavirus vaccine resumed following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so, the company said on Saturday.
Late-stage trials of the experimental vaccine, one of the most advanced in development, were suspended this week after illness in a study subject in Britain.
“The standard review process resulted in a voluntary pause in vaccination in all global trials to allow for review of safety data by independent committees and international regulators,” said AstraZeneca.
“The UK committee has concluded its investigations and recommended to the MHRA that it is safe to resume trials in the UK.”
The company said it could not release further medical information.
“All investigators and trial participants will be updated with relevant information and it will be disclosed in global clinical registries, in accordance with clinical trial and regulatory standards.”
Meanwhile, the Indian company Serum Institute of India said it would resume clinical trials of AstraZeneca’s COVID-19 candidate vaccine after obtaining permission from the Controller General of Drugs of India (DCGI). — Reuters / PTI
